Oclusão da veia retiniana

Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013 Mar;155(3):429-37.e7. Resumo

Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011 Oct;118(10):2041-9. Resumo

Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011 Dec;118(12):2453-60. Resumo

The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the central vein occlusion study group M report. Ophthalmology. 1995 Oct;102(10):1425-33. Resumo

Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016 Feb;123(2):330-336.Texto completo  Resumo

Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Aug;118(8):1594-602. Resumo

1. Song P, Xu Y, Zha M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019 Jun;9(1):010427.Texto completo  Resumo

2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996 Oct;114(10):1243-7. Resumo

3. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-41.Texto completo  Resumo

4. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994 Apr 15;117(4):429-41. Resumo

5. Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol. 2008 Apr;126(4):513-8. Resumo

6. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997 Apr;115(4):486-91. [Erratum in: Arch Ophthalmol 1997 Oct;115(10):1275.] Resumo

7. Hayreh SS. Central retinal vein occlusion. Ophthalmol Clin North Am. 1998 Dec 1;11(4):559-90.Texto completo

8. Green WR, Chan CC, Hutchins GM, et al. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina. 1981;1(1):27-55. Resumo

9. Zhao J, Sastry SM, Sperduto RD, et al. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology. 1993 Mar;100(3):423-8. Resumo

10. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol. 1990 Mar 15;109(3):298-302. Resumo

11. Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol. 1989 Jul;107(7):998-1000. Resumo

12. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480-7.Texto completo  Resumo

13. Dodson PM, Galton DJ, Hamilton AM, et al. Retinal vein occlusion and the prevalence of lipoprotein abnormalities. Br J Ophthalmol. 1982 Mar;66(3):161-4.Texto completo  Resumo

14. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol. 1996 Mar;80(3):203-8.Texto completo  Resumo

15. Ciardella AP, Yannuzzi LA, Freund KB, et al. Factor V Leiden, activated protein C resistance, and retinal vein occlusion. Retina. 1998;18(4):308-15. Resumo

16. Gutman FA. Evaluation of a patient with central retinal vein occlusion. Ophthalmology. 1983 May;90(5):481-3. Resumo

17. Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002 Mar;240(3):180-96. Resumo

18. Abu El-Asrar AM, Abdel Gader AG, Al-Amro S, et al. Hypercoagulable states in patients with retinal venous occlusion. Doc Ophthalmol. 1998;95(2):133-43. Resumo

19. The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993 Sep 15;116(3):286-96. Resumo

20. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993 May-Jun;37(6):393-417. [Erratum in: Surv Ophthalmol 1993 Jul-Aug;38(1):88.] Resumo

21. Hayreh SS, Klugman MR, Beri M, et al. Differentiation of ischemic from nonischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol. 1990;228(3):201-17. Resumo

22. US Preventative Services Task Force. Final recommendation statement - impaired visual acuity in older adults: screening. May 2022 [internet publication].Texto completo

23. Chou R, Bougatsos C, Jungbauer R, et al. Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 Jun 7;327(21):2129-40.Texto completo  Resumo

24. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013 Mar;155(3):429-37.e7. Resumo

25. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011 Oct;118(10):2041-9. Resumo

26. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013 Mar;97(3):278-84.Texto completo  Resumo

27. Epstein DL, Algvere PV, von Wendt G, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology. 2012 Jun;119(6):1184-9.Texto completo  Resumo

28. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol. 2007 Apr;143(4):601-6. Resumo

29. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007 Oct;27(8):1004-12. Resumo

30. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina. 2007 Oct;27(8):1013-9. Resumo

31. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008 Apr;92(4):518-22. Resumo

32. Scott IU, VanVeldhuisen PC, Ip MS, et al; SCORE2 Investigator Group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA. 2017 May 23;317(20):2072-87.Texto completo  Resumo

33. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003 Sep;136(3):419-25. Resumo

34. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004 Aug;122(8):1131-6. Resumo

35. Bashshur ZF, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004 Aug;122(8):1137-40. Resumo

36. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol. 2005 May;139(5):860-6. Resumo

37. Cekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina. 2005 Oct-Nov;25(7):846-50. Resumo

38. Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina. 2006 Oct;26(8):889-95. Resumo

39. Goff MJ, Jumper JM, Yang SS, et al. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina. 2006 Oct;26(8):896-901. Resumo

40. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009 Sep;127(9):1101-14. Resumo

41. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011 Dec;118(12):2453-60. Resumo

42. Gerding H, Monés J, Tadayoni R, et al. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol. 2015 Mar;99(3):297-304.Texto completo  Resumo

43. Ming S, Xie K, Yang M, et al. Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review. BMJ Open. 2020 Jun 28;10(6):e032128.Texto completo  Resumo

44. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the central vein occlusion study group M report. Ophthalmology. 1995 Oct;102(10):1425-33. Resumo

45. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central retinal vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. 1995 Oct;102(10):1434-44. Resumo

46. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):144-6. Resumo

47. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006 Dec;142(6):1054-6. Resumo

48. Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008 Feb;28(1):59-61. Resumo

49. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007 Aug;16(5):437-9. Resumo

50. Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016 Feb;123(2):330-336.Texto completo  Resumo

51. National Institute for Health and Care Excellence. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion. Sep 2016 [internet publication].Texto completo

52. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Aug;118(8):1594-602. Resumo

53. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012 Apr;119(4):802-9. Resumo

54. Yilmaz T, Cordero-Coma M. Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2012 Jun;250(6):787-93. Resumo

55. Spandau U, Wickenhäuser A, Rensch F, et al. Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand. 2007 Feb;85(1):118-9. Resumo

56. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007 Apr-May;27(4):419-25. Resumo

57. Wu L, Arevalo JF, Roca JA, et al; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 2008 Feb;28(2):212-9. Resumo

58. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008 Mar;92(3):351-5. Resumo

59. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009 Sep;127(9):1115-28. Resumo

60. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol. 1986 Jan;104(1):34-41. Resumo

61. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984 Sep 15;98(3):271-82. Resumo

62. Tadayoni R, Waldstein SM, Boscia F, et al; BRIGHTER Study Group. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017 Dec;124(12):1778-87.Texto completo  Resumo

63. Scott IU, Vanveldhuisen PC, Oden NL, et al; SCORE Study Investigator Group. Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study: SCORE Study Report 14. Arch Ophthalmol. 2012 Dec;130(12):1517-24. Resumo

64. Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019 May 28;9(5):e022031.Texto completo  Resumo

65. Shalchi Z, Mahroo O, Bunce C, et al. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2020 Jul 7;7:CD009510.Texto completo  Resumo

66. Varma R, Bressler NM, Suñer I, et al; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012 Oct;119(10):2108-18. Resumo

67. Pournaras JA, Nguyen C, Vaudaux JD, et al. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results. Klin Monastbl Augenheilkd. 2008 May;225(5):397-400. Resumo

68. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007 Apr;41(4):614-25. Resumo

69. Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration : early results of a prospective, double-masked, randomized clinical trial. Am J Ophthalmol. 2009 Dec;148(6):875-82.e1. Resumo

70. Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of age-related macular degeneration. Retina. 2009 Sep;29(8):1067-73. Resumo

71. Martin DF, Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388-98. Resumo

72. Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2009;223(6):370-5. Resumo

73. Chang TS, Kokame G, Casey R, et al. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina. 2009 Oct;29(9):1235-41. Resumo

74. Gewaily D, Muthuswamy K, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2015 Sep 9;(9):CD007324.Texto completo  Resumo

75. ClinicalTrials.gov. The Standard care vs. Corticosteroid for REtinal vein occlusion (SCORE) study: two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema (NCT00105027). Mar 2018 [internet publication].Texto completo

76. American Academy of Ophthalmology. The use of biosimilars in ophthalmic practice - 2022. Jan 2022 [internet publication].Texto completo

77. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. 1995 Apr;113(4):456-62. Resumo

78. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol. 1998 Jan;116(1):43-52. Resumo

79. Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina. 2001;21(5):408-15. Resumo

80. Garcia-Arumii J, Boixadera A, Martinez-Castillo V, et al. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol. 2003 Oct;121(10):1385-91. Resumo

81. Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol. 2003 Nov;136(5):814-9. Resumo

82. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc. 1996;94:471-504.Texto completo  Resumo

83. Glacet-Bernard A, Kuhn D, Vine AK, et al. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000 Jun;84(6):609-13.Texto completo  Resumo

84. Weiss JN. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol. 1998 Jul;126(1):142-4. Resumo

85. Bynoe LA, Weiss JN. Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol. 2003 Mar;135(3):382-4. Resumo

86. Bynoe LA, Hutchins RK, Lazarus HS, et al. Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons. Retina. 2005 Jul-Aug;25(5):625-32. Resumo

87. Squizzato A, Manfredi E, Bozzato S, et al. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost. 2010 Feb;103(2):271-6. Resumo

88. Feltgen N, Junker B, Agostini H, et al. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmology. 2007 Apr;114(4):716-23. Resumo

89. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020 Jan;127(1):72-84.Texto completo  Resumo

90. U.S. National Library of Medicine. Clinical trial. Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR). Jun 2021 [internet publication].Texto completo

91. U.S. National Library of Medicine. Clinical trials. Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN). Jun 2021 [internet publication].Texto completo

92. Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021 Jan;128(1):89-99.Texto completo  Resumo